Zobrazit v EDS

Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study

Uloženo v:
Podrobná bibliografie
Název: Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study
Autoři: Huang, Ying, Chen, Siwei, Pan, Huachun, Yang, Shumin, Cheng, Wenke
Zdroj: BMC Cardiovasc Disord
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-12 (2024)
Informace o vydavateli: Springer Science and Business Media LLC, 2024.
Rok vydání: 2024
Témata: Adult, Male, Time Factors, Blood Pressure, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Cause of Death, Diseases of the circulatory (Cardiovascular) system, Humans, Prospective Studies, Mortality, Aged, Apolipoproteins B, Research, National Health and Nutrition Examination Survey, Middle Aged, All-cause mortality, Cardiovascular disease, Nutrition Surveys, Prognosis, 3. Good health, Cardiovascular Diseases, Heart Disease Risk Factors, RC666-701, Apolipoprotein B-100, Hypertension, Hypertension/blood [MeSH], Aged [MeSH], Risk Assessment [MeSH], Cardiovascular Diseases/diagnosis [MeSH], Risk Factors [MeSH], Hypertension/diagnosis [MeSH], Apolipoproteins B/blood [MeSH], Apolipoprotein B-100/blood [MeSH], Cause of Death [MeSH], Blood Pressure [MeSH], Heart Disease Risk Factors [MeSH], Male [MeSH], United States/epidemiology [MeSH], Cardiovascular Diseases/mortality [MeSH], Female [MeSH], Hypertension/mortality [MeSH], Adult [MeSH], Biomarkers/blood [MeSH], Humans [MeSH], Prospective Studies [MeSH], Nutrition Surveys [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Apolipoprotein B, Cardiovascular Diseases/blood [MeSH], Prognosis [MeSH], Female, Biomarkers
Popis: Background Dyslipidemia frequently coexists with hypertension in the population. Apolipoprotein B (ApoB) is increasingly considered a more potent predictor of cardiovascular disease (CVD). Abnormal levels of serum ApoB can potentially impact the mortality risk. Methods The prospective cohort study employed data from the National Health and Nutrition Examination Survey (NHANES), which was performed between 2005 and 2016, with follow-ups extended until December 2019. Serum ApoB concentrations were quantified using nephelometry. In line with the NHANES descriptions and recommendations, the reference ranges for ApoB concentrations are 55–140 and 55–125 mg/dL for men and women, respectively. Participants were categorized into low, normal, and high ApoB levels. The low and high groups were combined into the abnormal group. In this study, all-cause mortality (ACM) and CVD mortality (CVM) were the endpoints. Survey-weighted cox hazards models were used for evaluating the correlation between serum ApoB levels and ACM and CVM. A generalized additive model (GAM) was employed to examine the dose-dependent relationship between ApoB levels and mortality risk. Results After a median of 95 (interquartile range: 62–135) months of follow-up, 986 all-cause and 286 CVD deaths were recorded. The abnormal ApoB group exhibited a trend toward an elevated risk of ACM in relative to the normal group (HR 1.22, 95% CI: 0.96–1.53). The risk of CVM was elevated by 76% in the ApoB abnormal group (HR 1.76, 95% CI: 1.28–2.42). According to the GAM, there existed a nonlinear association between serum ApoB levels and ACM (P = 0.005) and CVM (P = 0.009). Conclusions In the US hypertensive population, serum Apo B levels were U-shaped and correlated with ACM and CVM risk, with the lowest risk at 100 mg/dL. Importantly, abnormal Apo B levels were related to an elevated risk of ACM and CVM. These risks were especially high at lower Apo B levels. The obtained findings emphasize the importance of maintaining appropriate Apo B levels to prevent adverse outcomes in hypertensive individuals.
Druh dokumentu: Article
Other literature type
Jazyk: English
ISSN: 1471-2261
DOI: 10.1186/s12872-024-03949-1
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38789961
https://doaj.org/article/cc37c86adfaa4f6bb0e3a9d1afd2743b
https://repository.publisso.de/resource/frl:6503325
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (http://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Přístupové číslo: edsair.doi.dedup.....1f0113019f932ccfec863da100939812
Databáze: OpenAIRE
Popis
Abstrakt:Background Dyslipidemia frequently coexists with hypertension in the population. Apolipoprotein B (ApoB) is increasingly considered a more potent predictor of cardiovascular disease (CVD). Abnormal levels of serum ApoB can potentially impact the mortality risk. Methods The prospective cohort study employed data from the National Health and Nutrition Examination Survey (NHANES), which was performed between 2005 and 2016, with follow-ups extended until December 2019. Serum ApoB concentrations were quantified using nephelometry. In line with the NHANES descriptions and recommendations, the reference ranges for ApoB concentrations are 55–140 and 55–125 mg/dL for men and women, respectively. Participants were categorized into low, normal, and high ApoB levels. The low and high groups were combined into the abnormal group. In this study, all-cause mortality (ACM) and CVD mortality (CVM) were the endpoints. Survey-weighted cox hazards models were used for evaluating the correlation between serum ApoB levels and ACM and CVM. A generalized additive model (GAM) was employed to examine the dose-dependent relationship between ApoB levels and mortality risk. Results After a median of 95 (interquartile range: 62–135) months of follow-up, 986 all-cause and 286 CVD deaths were recorded. The abnormal ApoB group exhibited a trend toward an elevated risk of ACM in relative to the normal group (HR 1.22, 95% CI: 0.96–1.53). The risk of CVM was elevated by 76% in the ApoB abnormal group (HR 1.76, 95% CI: 1.28–2.42). According to the GAM, there existed a nonlinear association between serum ApoB levels and ACM (P = 0.005) and CVM (P = 0.009). Conclusions In the US hypertensive population, serum Apo B levels were U-shaped and correlated with ACM and CVM risk, with the lowest risk at 100 mg/dL. Importantly, abnormal Apo B levels were related to an elevated risk of ACM and CVM. These risks were especially high at lower Apo B levels. The obtained findings emphasize the importance of maintaining appropriate Apo B levels to prevent adverse outcomes in hypertensive individuals.
ISSN:14712261
DOI:10.1186/s12872-024-03949-1